Targeted Deletion of ER Chaperone GRP94 in the Liver Results in Injury, Repopulation of GRP94-Positive Hepatocytes, and Spontaneous Hepatocellular Carcinoma Development in Aged Mice

Neoplasia (United States)

Volumn 16, Issue 8, 2014, Pages 617-626

  Chen, Wan Ting ^a   Ha, Dat ^a   Kanel, Gary ^b   Lee, Amy S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991531389     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.07.005     Document Type: Article

References (50)

1. Ni M., Lee A.S. ER chaperones in mammalian development and human diseases. FEBS Lett 2007, 581:3641-3651.
2. Lee A.S. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer 2014, 14:263-276.
3. Eletto D., Dersh D., Argon Y. GRP94 in ER quality control and stress responses. Semin Cell Dev Biol 2010, 21:479-485.
4. Liu B., Staron M., Hong F., Wu B.X., Sun S., Morales C., Crosson C.E., Tomlinson S., Kim I., Wu D., et al. Essential roles of grp94 in gut homeostasis via chaperoning canonical Wnt pathway. Proc Natl Acad Sci U S A 2013, 110:6877-6882.
5. Maynard J.C., Pham T., Zheng T., Jockheck-Clark A., Rankin H.B., Newgard C.B., Spana E.P., Nicchitta C.V. Gp93, the Drosophila GRP94 ortholog, is required for gut epithelial homeostasis and nutrient assimilation-coupled growth control. Dev Biol 2010, 339:295-306.
6. 2+-binding and antiapoptotic properties is a novel proteolytic target of calpain during etoposide-induced apoptosis. J Biol Chem 1999, 274:28476-28483.
7. Chen W.T., Tseng C.C., Pfaffenbach K., Kanel G., Luo B., Stiles B.L., Lee A.S. Liver-specific knockout of GRP94 in mice disrupts cell adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis. Hepatology 2014, 59:947-957.
8. Hua Y., White-Gilbertson S., Kellner J., Rachidi S., Usmani S.Z., Chiosis G., Depinho R., Li Z., Liu B. Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma. Clin Cancer Res 2013, 19:6242-6251.
9. Morales C., Rachidi S., Hong F., Sun S., Ouyang X., Wallace C., Zhang Y., Garret-Mayer E., Wu J., Liu B., et al. Immune chaperone gp96 drives the contributions of macrophages to inflammatory colon tumorigenesis. Cancer Res 2014, 74:446-459.
10. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
11. Bruix J., Boix L., Sala M., Llovet J.M. Focus on hepatocellular carcinoma. Cancer Cell 2004, 5:215-219.
12. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006, 25:3818-3822.
13. Lee J.S., Heo J., Libbrecht L., Chu I.S., Kaposi-Novak P., Calvisi D.F., Mikaelyan A., Roberts L.R., Demetris A.J., Sun Z., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006, 12:410-416.
14. Chiba T., Zheng Y.W., Kita K., Yokosuka O., Saisho H., Onodera M., Miyoshi H., Nakano M., Zen Y., Nakanuma Y., et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007, 133:937-950.
15. Chiba T., Seki A., Aoki R., Ichikawa H., Negishi M., Miyagi S., Oguro H., Saraya A., Kamiya A., Nakauchi H., et al. Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and -independent manners in mice. Hepatology 2010, 52:1111-1123.
16. Giannelli G., Mazzocca A., Fransvea E., Lahn M., Antonaci S. Inhibiting TGF-beta signaling in hepatocellular carcinoma. Biochim Biophys Acta 2011, 1815:214-223.
17. Wu K., Ding J., Chen C., Sun W., Ning B.F., Wen W., Huang L., Han T., Yang W., Wang C., et al. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 2012, 56:2255-2267.
18. Schmitz K.J., Wohlschlaeger J., Lang H., Sotiropoulos G.C., Malago M., Steveling K., Reis H., Cicinnati V.R., Schmid K.W., Baba H.A. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008, 48:83-90.
19. Nakagawa H., Maeda S. Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Pathol Res Int 2012, 2012. [Article ID 172894, 14 pages].
20. Hagiwara S., Kudo M., Nagai T., Inoue T., Ueshima K., Nishida N., Watanabe T., Sakurai T. Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br J Cancer 2012, 106:1997-2003.
21. Jin C., Samuelson L., Cui C.B., Sun Y., Gerber D.A. MAPK/ERK and Wnt/beta-Catenin pathways are synergistically involved in proliferation of Sca-1 positive hepatic progenitor cells. Biochem Biophys Res Commun 2011, 409:803-807.
22. Fu Y., Wey S., Wang M., Ye R., Liao C.P., Roy-Burman P., Lee A.S. Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium. Proc Natl Acad Sci U S A 2008, 105:19444-19449.
23. Heijmans J., van Lidth de Jeude J.F., Koo B.K., Rosekrans S.L., Wielenga M.C., van de Wetering M., Ferrante M., Lee A.S., Onderwater J.J., Paton J.C., et al. ER stress causes rapid loss of intestinal epithelial stemness through activation of the unfolded protein response. Cell Rep 2013, 3:1128-1139.
24. Chen W.T., Zhu G., Pfaffenbach K., Kanel G., Stiles B., Lee A.S. GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN. Oncogene 2014, [Epub ahead of print]. 10.1038/onc.2013.437.
25. Rosekrans S.L., Heijmans J., Büller N.V., Westerlund J., Lee A.S., Muncan V., van den Brink G.R. ER stress induces epithelial differentiation in the mouse oesophagus. Gut 2014, [Epub ahead of print]. 10.1136/gutjnl-2013-306347.
26. Gouw A.S., Clouston A.D., Theise N.D. Ductular reactions in human liver: diversity at the interface. Hepatology 2011, 54:1853-1863.
27. Williams M.J., Clouston A.D., Forbes S.J. Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. Gastroenterology 2014, 146:349-356.
28. Bissell D.M. Chronic liver injury, TGF-beta, and cancer. Exp Mol Med 2001, 33:179-190.
29. Di Tommaso L., Franchi G., Park Y.N., Fiamengo B., Destro A., Morenghi E., Montorsi M., Torzilli G., Tommasini M., Terracciano L., et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007, 45:725-734.
30. Inagaki Y., Okazaki I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007, 56:284-292.
31. Ikushima H., Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010, 10:415-424.
32. Mamuya F.A., Duncan M.K. aV integrins and TGF-beta-induced EMT: a circle of regulation. J Cell Mol Med 2012, 16:445-455.
33. Luo B., Lam B.S., Lee S.H., Wey S., Zhou H., Wang M., Chen S.Y., Adams G.B., Lee A.S. The endoplasmic reticulum chaperone protein GRP94 is required for maintaining hematopoietic stem cell interactions with the adult bone marrow niche. PLoS One 2011, 6:e20364. 10.1371/journal.pone.0039047.
34. Luo B., Tseng C.C., Adams G.B., Lee A.S. Deficiency of GRP94 in the hematopoietic system alters proliferation regulators in hematopoietic stem cells. Stem Cells Dev 2013, 22:3062-3073.
35. Ostrovsky O., Ahmed N.T., Argon Y. The chaperone activity of GRP94 toward insulin-like growth factor II is necessary for the stress response to serum deprivation. Mol Biol Cell 2009, 20:1855-1864.
36. Hijikawa T., Kaibori M., Uchida Y., Yamada M., Matsui K., Ozaki T., Kamiyama Y., Nishizawa M., Okumura T. Insulin-like growth factor 1 prevents liver injury through the inhibition of TNF-alpha and iNOS induction in D-galactosamine and LPS-treated rats. Shock 2008, 29:740-747.
37. Aksu I., Baykara B., Kiray M., Gurpinar T., Sisman A.R., Ekerbicer N., Tas A., Gokdemir-Yazar O., Uysal N. Serum IGF-1 levels correlate negatively to liver damage in diabetic rats. Biotech Histochem 2013, 88:194-201.
38. Cadamuro M., Morton S.D., Strazzabosco M., Fabris L. Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies. Transl Gastrointest Cancer 2013, 2:130-144.
39. Morris S.M., Baek J.Y., Koszarek A., Kanngurn S., Knoblaugh S.E., Grady W.M. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss. Hepatology 2012, 55:121-131.
40. Jeanes A., Gottardi C.J., Yap A.S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression?. Oncogene 2008, 27:6920-6929.
41. Wei Y., Van Nhieu J.T., Prigent S., Srivatanakul P., Tiollais P., Buendia M.A. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology 2002, 36:692-701.
42. Calvisi D.F., Ladu S., Conner E.A., Factor V.M., Thorgeirsson S.S. Disregulation of E-cadherin in transgenic mouse models of liver cancer. Lab Invest 2004, 84:1137-1147.
43. Osada T., Sakamoto M., Ino Y., Iwamatsu A., Matsuno Y., Muto T., Hirohashi S. E-cadherin is involved in the intrahepatic metastasis of hepatocellular carcinoma. Hepatology 1996, 24:1460-1467.
44. Tomlinson J.S., Alpaugh M.L., Barsky S.H. An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res 2001, 61:5231-5241.
45. Saha B., Chaiwun B., Imam S.S., Tsao-Wei D.D., Groshen S., Naritoku W.Y., Imam S.A. Overexpression of E-cadherin protein in metastatic breast cancer cells in bone. Anticancer Res 2007, 27:3903-3908.
46. Yanger K., Zong Y., Maggs L.R., Shapira S.N., Maddipati R., Aiello N.M., Thung S.N., Wells R.G., Greenbaum L.E., Stanger B.Z. Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev 2013, 27:719-724.
47. Lim S.O., Park S.G., Yoo J.H., Park Y.M., Kim H.J., Jang K.T., Cho J.W., Yoo B.C., Jung G.H., Park C.K. Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol 2005, 11:2072-2079.
48. Yao D.F., Wu X.H., Su X.Q., Yao M., Wu W., Qiu L.W., Zou L., Meng X.Y. Abnormal expression of HSP gp96 associated with HBV replication in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2006, 5:381-386.
49. Patel P.D., Yan P., Seidler P.M., Patel H.J., Sun W., Yang C., Que N.S., Taldone T., Finotti P., Stephani R.A., et al. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat Chem Biol 2013, 9:677-684.
50. Duerfeldt A.S., Peterson L.B., Maynard J.C., Ng C.L., Eletto D., Ostrovsky O., Shinogle H.E., Moore D.S., Argon Y., Nicchitta C.V., et al. Development of a Grp94 inhibitor. J Am Chem Soc 2012, 134:9796-9804.